This is a groundbreaking step toward advancing public health by using more effective and human-relevant methods instead of ...

We spoke with Josh Hoerner, general manager of Purisys, which specializes in a small volume custom synthesis and specialized ...

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Simulations Plus leverages AI-driven tools to revolutionize drug discovery, cut R&D costs, and capitalize on FDA regulatory ...

Novo Nordisk notified the Food and Drug Administration about several hundred units of fake semaglutide 1.0 mg in the US drug ...

On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy over its use of non-human primates, plunged 28 percent after the FDA issued ...

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

In a unanimous decision on Wednesday, the Supreme Court rejected an appeals court's conclusion that the Food and Drug ...

Ellen Behrend, VMD, PhD, MS, DACVIM (SAIM) explains the differences between bexagliflozin and velagliflozin, and how to determine if a patient is a good candidate ...

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...